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Abstract 
Background: In many low resource settings, the provision of government mental health care services is limited to 
specialized psychiatry units in urban hospital care facilities, where the most common treatment for common mental 
disorders (CMDs) is pharmacotherapy, occasionally with adjunct nonspecific psychological support. We aimed to 
evaluate the effectiveness of adding a low intensity, psychological intervention, Problem Management Plus (PM+) for 
CMDs into routine care in a specialized mental health care facility in Pakistan.
Methods: A two arm, single‑blind individual randomized controlled trial (RCT) was carried out with adults (N = 192), 
referred for psychological support by psychiatrists. The study participants were randomized (1:1) to PM + plus Treat‑
ment as Usual (TAU) (n = 96) or TAU only (n = 96). The primary outcomes were symptoms of anxiety and depression, 
measured by the Hospital Anxiety and Depression Scale (HADS) and functional impairment as measured by WHO 
Disability Assessment Schedule (WHODAS 2.0) at 20 weeks after baseline.
Results: The analysis was done on intention‑to‑treat principle. The linear mixed model analysis showed that at 
20 weeks after baseline, there was a significant reduction in symptoms of anxiety and depression (mean [SD], 16.23 
[8.81] vs 19.79 [7.77]; AMD, − 3.10; 95% CI, − 0.26 to − 5.76); p = 0.03 and improvement in functioning (mean [SD], 
22.94 [9.37] vs 27.37 [8.36]; AMD, − 4.35; 95% CI, − 1.45 to − 7.24); p = 0.004 in PM + plus TAU versus TAU arm. The 
follow‑up rate was 67% at primary end‑point.
Conclusions: Specialized care facilities in LMICs may consider adding brief, evidence‑based psychological treatments 
for CMDs to their routine care.
Trial Registration Australian New Zealand Clinical Trials Registry, ACTRN12616000381482. Registered March 23, 2016. 
Retrospectively registered, https ://www.anzct r.org.au/Defau lt.aspx/ ACTRN12616000381482
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Background
Common mental disorders (CMDs), such as anxiety 
and depression, are one of the leading causes of dis-
ability globally [1]. In low and middle-income countries 
(LMICs), the treatment gap for CMDs is more than 90% 
[2]. Despite the wide-spread recognition of this gap for 
CMDs in LMICs, the provision of government mental 
health care services is usually limited to specialized psy-
chiatry units, located in hospital care facilities [3]. Men-
tal health needs are evident in Pakistan, which has been 
affected by chronic adversity in the form of socio-polit-
ical instability, economic uncertainty, regional conflict 
and dislocation. These events have led to increased lev-
els of psychological and social suffering, including a high 
prevalence of mental disorders in Pakistan [4, 5].
A number of psychological intervention manuals—
mainly based on cognitive behavioral and interpersonal 
psychotherapy—have been developed and proven effec-
tive for treating CMDs in primary health care and com-
munity settings in LMICs [6–10] and meta-analyses 
suggest that such interventions are as effective as phar-
macotherapy [11]. The World Health Organization 
(WHO) recommends that both anti-depressants and 
psychological interventions should be available to people 
with depression [12]. A brief, multicomponent behavio-
ral WHO intervention called Problem Management Plus 
(PM +) was developed for the management of CMDs in 
settings affected by adversity [13]. There have been mul-
tiple trials of PM + delivered in individual and group for-
mats [9, 10, 14]. However, these studies have focused on 
evaluating the effectiveness of PM + to reduce CMDs in 
primary health care and community settings.
The mainstay of treatment for CMDs in many psychi-
atric units is pharmacotherapy [15], occasionally with 
adjunct nonspecific psychological support. It is thus 
valuable to evaluate whether evidence-based psychologi-
cal interventions can be effectively added in routine spe-
cialist health context to reduce the burden of CMDs in 
LMICs.
Methods
This study aimed to evaluate the effectiveness of adding 
PM + for CMDs to routine care in a specialized mental 
health care facility in Pakistan. We hypothesized that 
PM + in combination with Treatment-as-Usual (TAU) 
will be superior compared to TAU alone, to reduce the 
symptoms of depression and anxiety measured with 
Hospital Anxiety and Depression Scale (HADS) total 
score at 20 weeks after baseline.
Design
We conducted a single-blind individual randomized 
controlled trial (RCT) to evaluate the effectiveness of 
PM + plus Treatment-as-Usual (TAU) versus TAU alone 
in the treatment of CMDs in patients presenting in the 
outpatient department of Institute of Psychiatry, Rawal-
pindi, Pakistan. The study was conducted over the dura-
tion of 12  months. Ethical approval of the study was 
obtained from the Institutional Review and Ethics Board 
of the Rawalpindi Medical University and Allied Hospi-
tals Rawalpindi (ethical approval certificate number ERC/
RMU/23/05/2015). The full trial protocol is available 
online [16]. Trial registration: Australian New Zealand 
Clinical Trials Registry, ACTRN12616000381482. Regis-
tered Retrospectively on March 23, 2016.
Study settings
The participants were recruited from the Institute of 
Psychiatry (IoP), WHO Collaborating Centre for Mental 
Health Research and Training, Benazir Bhutto Hospital-
the public sector tertiary care hospital in Rawalpindi, 
Pakistan. IoP is the hub of mental health policy, services, 
training and research in Pakistan. It is the specialist refer-
ral facility for the patients with mental health problems 
presenting in the primary and secondary health care 
facilities in the north of Pakistan. Patient services include 
in-patients and outpatient services which are led by 
teams comprising of consultant psychiatrists and psy-
chologists, trainee psychiatrists and psychologists, social 
workers and interns.
Participants
The target population for this study was adult (age 
18–60  years) outpatient department attendees, referred 
for psychological support for depression, anxiety and 
stress related conditions by psychiatrists after clinical 
evaluation who (a) scored above 2 on a screening ques-
tionnaire for psychological distress (General Health Ques-
tionnaire-12; GHQ-12); [17, 18] and (b) scored above 
16 on a screening questionnaire for functional impair-
ments (WHO Disability Assessment Schedule – WHO-
DAS 2.0) [19]. As PM + is not suitable for the treatment 
of severe mental health problems (including psychosis or 
risk of suicide) [13], participants with imminent risk of 
suicide, severe mental disorder (e.g. psychotic disorders, 
Keywords: Low intensity psychological intervention, Cognitive behavioral therapy, Specialized mental health facility, 
Common mental disorders, Depression, Anxiety
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substance dependence), or severe cognitive impairment 
(e.g. severe intellectual disability, dementia) as assessed by 
psychiatrists, were excluded from the study.
Interventions
Problem Management plus (PM+)
The WHO PM + intervention (individual version) [13] 
is based on established principles of problem solving 
and behavioral techniques and is delivered in five weekly 
face-to-face sessions administered on an individual basis. 
The average duration of each session is 90 min. The two 
key features of WHO PM + program are (a) the program 
takes a task-shifting approach where non-specialists 
(workers without a professional license specific for men-
tal health care such as, in Pakistan, psychology gradu-
ates, nurses and community volunteers) can deliver this 
program to adults experiencing common mental health 
problems (e.g. anxiety, stress, depression and grief )  and 
(b) it is trans-diagnostic—it addresses a range of symp-
toms for common mental disorders and does not require 
an expert diagnosis of condition to qualify treatment. 
PM + providers in this study had a master’s degree 
(16 years of education) in psychology and received eight 
days training in PM + by the master trainer followed by 
fortnightly supervision meetings with the master trainer.
Treatment‑as‑Usual (TAU)
Treatment-as-usual in the outpatient department con-
sists of an initial assessment by trainee psychiatrists 
followed by an expert consultation on the case by con-
sultant psychiatrist. The main stay of treatment is phar-
macotherapy and psychological support where needed. 
A psychological support session comprises of brief semi-
structured psycho-education sessions for patients with 
depression and anxiety symptoms and training in anger 
and stress management strategies such as breathing exer-
cises. A complete record of services received by trial 
participants in both study arms was obtained using the 
Client Services Receipt Inventory (CSRI).
Primary outcomes
The primary outcomes were (a) symptoms of anxiety 
and depression measured using the Hospital Anxiety 
and Depression Scale (HADS) [20, 21] and (b) functional 
impairment as measured by WHODAS 2.0 [22] at 
20 weeks after baseline.
a) The HADS is a well-established 14-item scale con-
sisting of two subscales: HADS-A (anxiety, seven 
items, and scores range from 0–21) and HADS-D 
(depression, seven items, scores range from 0–21), 
where higher scores indicate more anxiety and/or 
depression. In our study, we used a previously vali-
dated Urdu version of HADS [20].
b) Functional impairment was assessed using the 
12-item WHO Disability Assessment Schedule 
(WHODAS 2.0) [22]. WHODAS 2.0 assesses par-
ticipants’ health-related difficulties in the level of 
functioning in six domains of life (understanding 
and communicating; moving and getting around; 
attending to one’s hygiene, dressing, eating and stay-
ing alone; interacting with other people; domestic 
responsibilities, leisure, work and school and joining 
in community activities, participating in society) over 
the past 30 days. WHODAS 2.0 has been extensively 
used in different populations and health conditions 
including mental health and established itself as gold 
standard to measure functioning [23].
All the study tools were administered in local (i.e. 
Urdu) language and have been previously used in the 
similar settings of Pakistan [9, 10, 24].
An independent assessment team, trained in the ethi-
cal conduct of research and assessments and blinded to 
the allocation status of the trial participants, conducted 
baseline and post-intervention assessments.
Secondary outcomes
The secondary clinical outcomes included;
The Patient Health Questionnaire-9 (PHQ-9), which 
is a 9-item instrument measuring presence and severity 
of depression during the past 2-weeks on a 4-point Lik-
ert scale ranging from ‘not at all’ to ‘nearly every day’. 
The PHQ-9 total severity score ranges from 0 to 27 [25]. 
Higher scores indicate more severe depression. We used 
the previously validated Urdu version of PHQ-9 [26, 27].
The 17 item Post Traumatic Stress Symptoms-Check-
list (PCL-C) was used to measure DSM-IV based post-
traumatic stress disorder symptoms. The participants are 
asked to rate their responses on a 5-point scale during 
the past week. The PCL-C has been used previously in 
Pakistan [28] and found to have good psychometric prop-
erties (Mushtaq, unpublished data, 2013). In the current 
study, we changed the reporting time of PCL from last 
month to last week to enhance the sensitivity of tool to 
detect change at the 3 months’ post-intervention.
Psychological profile outcome (PSYCHLOPS)—[29] 
assesses personally identified problems. It consists of four 
questions that encompass three domains: problems (2 
questions), functioning (1 question) and wellbeing (1 ques-
tion). Participants are asked to give free text responses to 
the problem and function domains. Responses are scored 
on an ordinal 6-point scale producing a maximum score of 
20 (6 points per domain). The PSYCHLOPs version admin-
istered at post-treatment and follow-up also includes an 
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overall evaluation question (determining self-rated out-
come ranging from ‘much better’ to ‘much worse’) in rela-
tion to the identified problem. PSYCHLOPS has been 
validated in primary care populations across several coun-
tries [30, 31].
The Multidimensional Scale of Perceived Social Support 
(MSPSS) [32] aims to measure perceived social support. 
It includes 12 items which cover three dimensions: sup-
port from family, friends and significant other. Each item 
is rated on a 7-point Likert-scale (1 = very strongly disagree; 
7 = very strongly agree). A total score is calculated by sum-
ming the responses of all items (range 12–84) with higher 
scores indicating higher levels of perceived social support. 
The MSPSS has been validated in Urdu [33].
Services accessed by participants were recorded using 
the Client Services Receipt Inventory (CSRI). The CSRI 
was developed for the collection of data on service utili-
zation and related characteristics of people with mental 
disorders, as the basis for calculating the costs of care for 
mental health cost-effectiveness research [34]. It has been 
previously used in Pakistan and India [34, 35].
Procedure
Patients who presented at the outpatient department 
between July 2015 and November 2016 for treatment of 
CMDs were evaluated by a psychiatrist. After clinical eval-
uation, if the psychiatrist decided psychological support 
was indicated, s/he introduced the study and took verbal 
consent for participation in the study. Written informed 
consent was obtained from eligible participants by the 
study coordinator. Participants were randomized to inter-
vention or control arm on a 1:1 basis using computerized 
software by an independent researcher. The allocation 
concealment was ensured by keeping random sequence in 
sequentially numbered, opaque, sealed envelopes, at the 
off-site center. The intervention arm participants received 
a total of five weekly individual sessions of PM + program 
by PM + providers and TAU from the psychiatrists/psy-
chologists. The control arm participant received TAU from 
the psychiatrist/psychologists at the mental health facility. 
Post-treatment assessments were carried out at two-time 
points a) seven-weeks after baseline and b) 20 weeks after 
baseline. Participants who developed severe psychiatric 
problems (e.g., psychosis, imminent suicidality) at follow-
up were referred to psychiatrists for specialist care (n = 3).
Statistical analysis
Sample size calculation was based on a multicenter study 
of culturally-adapted cognitive behavioral therapy (CBT)-
based intervention conducted in Pakistan that used the 
HADS as the primary outcome measure [36]. A two-
point reduction in HADS depression score between the 
intervention and control arm is considered to be clini-
cally relevant [36]. With p < 0.05 and 90% power, a total of 
96 participants were needed. Accounting for an expected 
drop-out rate of 50%, the total sample size was 192 par-
ticipants, who were equally randomized to PM + (n = 96) 
and TAU (n = 96).
The data was analyzed using an Intent-To-Treat (ITT) 
analysis approach. The primary outcome was summa-
rized using number of participants (n), means and stand-
ard deviations (SD). To estimate the treatment effect, a 
linear mixed model was employed for the primary end-
point analysis, which had treatment, visit, interaction 
between treatment and visit as fixed effects, baseline 
measurement of primary endpoint as covariate, and sub-
ject as random effects. The mean difference between two 
treatment arms at each visit/time together with its 95% 
confidence interval was derived from the mixed model. 
Covariate-adjusted mixed model of primary endpoint 
(20  weeks after baseline) was also performed by adding 
pre-specified covariates at baseline into the above model. 
Secondary continuous outcomes were analyzed in a simi-
lar way. Missing data was treated as missing at random in 
the mixed model analysis and no imputation of primary 
and secondary endpoints was made. All analyses were 
performed using SAS 9.3.
Results
489 patients were assessed for eligibility. 192 participants, 
who met the inclusion criteria and provided informed 
consent were enrolled in the trial and randomly allocated 
(1:1) to PM + plus TAU (n = 96) and TAU arms (n = 96) 
(Fig.  1). The follow-up rate for primary outcome at the 
primary endpoint (20 weeks after baseline) was 64.5% (62 
of 96 participants) in the intervention arm and 69.79% 
(67 of 96 participants) in the control arm. There were no 
significant differences between the two arms in demo-
graphic characteristics and symptom scores at base-
line. The mean (± SD) age of the participants was 34.05 
(± 10.47) years. 68% (128/192) of the participants were 
females (Table 1). 
58% of participants attended 3 or more sessions of 
PM + intervention. The mean number of intervention 
sessions attended by trial participants was 2.84 (± 2.16). 
Each session lasted for an average of 90  min. The qual-
ity of intervention delivery was assessed by completing a 
self-check for each session by the PM + providers, sup-
ported by peer-supervision and fortnightly supervisions 
with the mental health specialist via Skype. In terms of 
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Fig. 1 Participants’ flow
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medication, 36/64 (56%) participants in PM + and 49/67 
(73%) participants in TAU reported receiving a prescrip-
tion of psychotropic medicines.(Table 2).
Seven-weeks after baseline, the intervention arm 
had significantly lower scores on HADS (mean [SD], 
16.72[8.44] vs 21.0 [7.88]; adjusted mean difference 
[AMD], 4.35; 95% CI, 1.71 to 6.99). At 20  weeks after 
baseline, the intervention arm had significantly lower 
scores than the control arm on HADS (mean [SD], 16.23 
[8.81] vs 19.79 [7.77]; AMD, 3.10; 95% CI, 0.26 to 5.76). 
Seven-weeks after baseline, the intervention arm had 
significantly lower scores on HADS-A (mean [SD], 8.56 
[5.00] vs 11.08 [4.90]; AMD, 2.41; 95% CI, 0.77 to 4.04) 
and HADS-D (mean [SD], 8.16 [4.17] vs 9.92 [4.37]; 
AMD, 1.85; 95% CI, 0.41 to 3.29). At 20 weeks after base-
line, the intervention arm had significantly lower scores 
than the control arm on HADS-A (mean [SD], 8.17 [5.12] 
vs 10.12 [4.79]; AMD, 1.69; 95% CI, − 0.02 to 3.41), how-
ever, there was no significant difference between two 
arms on HADS-D (mean [SD], 8.04 [4.89] vs 9.67 [3.94]; 
AMD, 1.30; 95% CI, − 0.21 to 2.81).(Table 3).
Seven-weeks after baseline, the intervention arm had 
significantly lower scores on WHODAS 2.0 (mean [SD], 
25.20[8.97] vs 28.41 [8.19]; AMD, 3.16 95% CI, 0.85to 
6.38). At 20 weeks after baseline, the difference of WHO-
DAS 2.0 scores between intervention arm and control 
arm was sustained (mean [SD], 22.94 [9.37] vs 27.37 
[8.36]; AMD, 4.35; 95% CI, 1.45 to 7.24).
At 20  weeks after baseline, there was a significant 
reduction in the level of posttraumatic stress in the 
intervention arm (mean [SD], 32.93[14.21] compared to 
the control arm 39.08 [15.75]; AMD, 5.39; 95% CI, 0.02 
Table 1 Demographic characteristics of the study participants (n, %)






Age (mean ± SD) 33.03 ± 9.94 35.07 ± 10.95 34.05 ± 10.47
Gender
 Male 32 (33.3) 28 (29.2) 60(31.9)
 Female 62 (64.6) 66 (68.8) 128 (68)
Education
 Uneducated 15 (15.6) 25 (26) 40 (20.8)
 Completed primary (grade 5) 20 (20.8) 12 (12.5) 32 (16.7)
 Completed middle (grade 8) 9 (9.4) 13 (13.5) 22(11.5)
 Completed matriculate (grade 10) 16 (16.7) 14 (14.6) 30 (15.6)
 Completed College and University (grade 11–16) 36 (37.5) 30 (31.3) 66 (34.4)
Marital status
 Never married 28 (29.8) 19 (19.8) 47(24.5)
 Currently married 61 (63.5) 69 (71.9) 130 (67.7)
 Separated 1 (1.0) 2 (2.1) 3 (1.6)
 Divorced 3 (3.1) 2 (2.1) 5 (2.6)
 Widowed 3 (3.1) 4 (4.2) 7 (3.6)
Employment status
 Employed 31 (32.3) 26 (27.1) 57 (29.7)
 Not employed 65 (67.7) 70 (72.9) 135 (70.3)
Occupation
 Paid work 24 (25.8) 20 (21.3) 44 (22.9)
 Self‑employed 10 (10.8) 8 (8.5) 18(9.4)
 Student 2 (2.2) 3 (3.2) 5(2.6)
 Keeping house/homemaker 14 (15.1) 18 (19.1) 32 (16.7)
 Retired 0 (0.0) 2 (2.1) 2 (1)
 Unemployed (health reasons) 2 (2.2) 1 (1.1) 3 (1.6)
 Unemployed (other reasons) 41 (44.1) 42 (44.7) 83 (43.2)
Living structure
 Nuclear 49 (51.0) 47 (49.5) 96(50)
 Joint/extended 47 (49.0) 48 (50.5) 95 (49.7)
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to 10.76). Similarly, there was significant reduction in 
the symptoms of depressive disorder in the interven-
tion arm (PHQ-9: mean [SD], 7.16[6.23] compared to 
the control arm 10.29[6.79]; AMD, 2.91; 95% CI, 0.60 to 
5.22) at 20 weeks after baseline. However, no significant 
differences were observed in the scores of PSYCHLOPS 
(mean[SD], 8.98(5.93) vs 10.62[4.99]; AMD, 1.63; 95% 
CI, − 0.24 to 3.51), and social support (mean[SD], 
56.61[17.35] vs 52.57[14.70]; AMD, − 2.24; 95% CI, 
− 7.90 to 3.42) between the two arm at 20  weeks after 
baseline.
The findings from covariate adjusted analysis showed 
that, after controlling for the baseline measurements (i.e. 
age, gender, severity on HADS), there was significant 
improvement in the intervention arm than TAU arm at 




The addition of PM + intervention to routine care in 
a specialist mental health facility in Pakistan led to 
improvements in symptoms of anxiety, depression, 
post-traumatic stress, and functioning at seven and 
20 weeks after baseline compared to routine care alone. 
PM + involves evidence based psychological strategies 
(including problem solving, stress management, behav-
ioral activation, and strengthening social support) that 
Table 2 Health services utilization across two arms after 20-weeks after baseline
Due to multiplicity of contacts with service providers and treatments received, the table reports frequency of contacts and prescribed treatment; 3 in intervention and 
2 participants in TAU were hospitalized during the study
Health service providers accessed PM+ ( f) TAU ( f)
Psychiatrist 45 49
Specialist doctor 21 33
General doctor 16 11
Pharmacist 1 2
Traditional healer 2 1
Other mental health worker 2 –
Number of visits
 3 visits 8 13
 2 visits 30 32
 1 visit 54 65
Location
 Public hospital 47 53
 Private hospital 11 6
 Local health centre – 5
Reasons for visit
 Follow‑up visit for treatment of depression or anxiety problems 50 60
 Sleep problems 10 13
 Acute aggravation of mental health problems 6 13
 Other mental health problems e.g. maternal/perinatal mental health condition 15 16
 Infectious diseases and injuries 2 2
Medications
A. Antidepressants (n = 58)
  SSRIs 22 31
  TCAs 2 3
 B. Anxiolytics 8 9
 C. Mood stabilizers 2 1
 D. Anti‑psychotics 2 5
 E. Multi‑vitamins 8 5
 F. Analgesics 4 3
 G. Others (anti‑ hypertensive, anti‑diabetic, thyroid related) 6 9
Average duration of consultation (in minutes) M(SD); min–max 7.62 (± 2.57); 3–15 8.85 (± 3.99); 2–20
Average consultation fee paid (in PKR) M(SD); min–max 32 (± 129.9): 0–700 3.10 (± 14.79); 0–100
Page 8 of 12Hamdani et al. Int J Ment Health Syst           (2021) 15:11 
seek to ameliorate the symptoms of anxiety and depres-
sion [13]. It has been evaluated with adults affected by 
adversity and experiencing psychological distress in 
a number of studies conducted in low resource con-
texts and settings, globally [9, 10, 14, 24]. The results of 
the current study demonstrate that low intensity psy-
chological intervention delivered by non-specialists, 
can improve the symptoms of anxiety and depression 
among adults in a specialist mental health care facility.
A key strength of the current study is that, we com-
pared two active interventions for treatment of CMDs 
in a specialist mental health care facility in Pakistan 
(PM + plus routine care versus routine care alone). The 
results demonstrated noticeable gains in the treatment 
Table 3 Summary statistics and results from mixed-model analysis of primary and secondary outcomes
TAU Treatment as usual, PM + Problem Management Plus, HADS Hospital Anxiety and Depression Scales (subscale score range: 0–21; higher scores indicate elevated 
anxiety or depression, respectively), WHODAS WHO Disability Adjustment Scale (total score range: 0–48; higher scores indicate more severe impairment), PCL 
Posttraumatic Stress Disorder Checklist (total score range: 17–85; higher scores indicate more severe PTSD severity), PHQ Patient Health Questionnaire (total score 
range: 0–27; higher scores indicate more severe depression, PSYCHLOPS Psychological Outcome Profiles (total score range: 0–20; higher scores indicate poorer 
outcome)
Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline
Primary and secondary outcomes Visit PM + (N = 96) TAU (N = 96) Difference in least squares 
mean (95% CI)
P-value
N M (SD) N M (SD)
Descriptive statistics n, mean (SD)
 HADS Anxiety Pre‑treatment 95 13.44 (3.67) 96 12.90 (4.02)
Post‑treatment 73 8.56 (5.00) 73 11.08 (4.90) − 2.41 (− 4.04 to − 0.77) 0.004
Follow‑up 62 8.17 (5.12) 67 10.12 (4.79) − 1.69 (− 3.41 to 0.02) 0.05
 HADS Depression Pre‑treatment 95 12.18 (3.99) 96 10.80 (3.72)
Post‑treatment 73 8.16 (4.17) 73 9.92 (4.37) − 1.85 (− 3.29 to − 0.41) 0.01
Follow‑up 62 8.04 (4.89) 67 9.67 (3.94) − 1.30 (− 2.81 to 0.21) 0.09
 HADS Pre‑treatment 95 25.62 (6.61) 96 23.70 (6.07)
Post‑treatment 73 16.72 (8.44) 73 21.00 (7.88) − 4.35 (− 6.99 to − 1.71) 0.002
Follow‑up 62 16.23 (8.81) 67 19.79 (7.77) − 3.10 (− 5.76 to − 0.26) 0.03
 WHODAS Pre‑treatment 96 33.41 (7.17) 96 32.77 (7.77)
Post‑treatment 74 25.20 (8.97) 74 28.41 (8.19) − 3.16 (− 6.38 to − 0.85) 0.01
Follow‑up 62 22.94 (9.73) 67 27.37 (8.36) − 4.35 (− 7.24 to − 1.45) 0.004
 PCL Pre‑treatment 96 49.78 (13.99) 96 49.86 (13.66)
Post‑treatment 61 39.90 (15.89) 63 42.35 (15.73) − 2.69 (− 8.08 to 2.70) 0.32
Follow‑up 61 32.93 (14.21) 64 39.08 (15.75) − 5.39 (− 10.76 to − 0.02) 0.05
 PHQ Pre‑treatment 96 15.09 (5.17) 96 15.04 (4.99)
Post‑treatment 53 9.79 (6.71) 54 11.76 (6.51) − 2.18 (− 4.65 to 0.29) 0.08
Follow‑up 61 7.16 (6.23) 63 10.29 (6.79) − 2.91 (− 5.22 to − 0.60) 0.01
 Days of these difficulties present Pre‑treatment 92 20.9 3 (9.61) 93 20.89 (8.51)
Post‑treatment 66 13.98 (10.45) 67 18.10 (10.21) − 3.93 (− 7.44 to − 0.43) 0.03
Follow‑up 60 13.88 (11.17) 64 16.67 (9.59) − 2.80 (− 6.40 to 0.80) 0.13
 Days of total disability Pre‑treatment 91 11.22 (9.78) 92 10.82 (9.47)
Post‑treatment 65 5.03 (7.15) 67 7.82 (9.03) − 2.62 (− 5.29 to 0.06) 0.06
Follow‑up 60 5.82 (7.34) 64 8.00 (7.82) − 1.71 (− 4.46 to 1.03) 0.22
 Days of activity reduce Pre‑treatment 90 14.14 (10.26) 92 12.97 (10.19)
Post‑treatment 65 8.22 (8.40) 67 11.19 (9.58) − 2.72 (− 5.92 to 0.49) 0.10
Follow‑up 60 8.35 (9.57) 64 10.20 (9.69) − 1.92 (− 5.22 to 1.38)) 0.25
 Perceived social support Pre‑treatment 96 51.92 (16.60) 96 52.74 (17.11)
Post‑treatment 73 55.53 (17.70) 74 51.43 (18.03) 3.85 (− 4.55 to 9.25) 0.16
Follow‑up 61 56.61 (17.35) 65 52.57 (14.70) 2.24 (− 3.42 to 7.90) 0.43
 PSYCHLOPS Pre‑treatment 96 15.39 (3.65) 95 14.94 (3.77)
Post‑treatment 67 9.31 (5.68) 69 11.55 (5.01) − 2.40 (− 4.19 to − 0.60) 0.009
Follow‑up 61 8.98 (5.93) 61 10.62 (4.99) − 1.63 (− 3.51 to 0.24) 0.09
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of anxiety and depression symptoms with addition of 
PM + to ongoing routine care that consisted of pharma-
cotherapy in most cases. The findings of our study are 
consistent with a systematic review and meta-analysis 
of literature by Cuijpers et al. [11], which concluded that 
pharmacotherapy and psychotherapy both contribute 
equally and independently to the effects of combined 
treatment. Hence, PM + may be a feasible and effec-
tive treatment option in outpatient psychiatry depart-
ments in LMICs, especially, where there are currently no 
defined psychological interventions available. However, 
further studies with placebo and combined pharmaco-
therapy and psychotherapy may be designed to under-
stand the clinical advantage of combined treatment with 
PM + intervention in tertiary care facilities.
Another strength of this study is the finding that non-
specialists can effectively deliver the PM + intervention 
to improve treatment outcomes for CMDs in a specialist 
mental health care facility in Pakistan. There is an urgent 
need to expand the mental health care workforce to meet 
Table 4 Summary results from  post  hoc mixed-model analysis of  primary and  secondary outcomes, with  baseline 
measurement (i.e. age, gender, HADS) included as covariate
HADS Hospital Anxiety and Depression Scale, WHODAS WHO Disability Assessment Schedule 2.0, PCL Post-traumatic stress disorder checklist, PHQ Patient Health 
Questionnaire, PSYCHLOPS Psychological Outcome Profile
Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline
Primary and secondary outcomes Visit Difference in least squares mean for intervention vs 
treatment as usual (95% CI)
P value
HADS Anxiety Pre‑treatment
Post‑treatment − 2.67 (− 4.32 to − 1.03) 0.002
Follow‑up − 1.84 (− 3.56 to − 0.13) 0.04
HADS Depression Pre‑treatment
Post‑treatment − 1.98 (− 3.41 to − 0.55) 0.007
Follow‑up − 1.43 (− 2.92 to 0.07) 0.06
HADS Pre‑treatment
Post‑treatment − 4.65 (− 7.27 to − 2.03) 0.0006
Follow‑up − 3.20 (− 5.92 to − 0.48) 0.02
WHO DAS Pre‑treatment
Post‑treatment − 3.81 (− 6.59 to − 1.04) 0.008
Follow‑up − 4.44 (− 7.34 to − 1.55) 0.003
PCL Pre‑treatment
Post‑treatment − 3.30 (− 8.71 to 2.12) 0.23
Follow‑up − 5.17 (− 11.08 to − 0.33) 0.04
PHQ Pre‑treatment
Post‑treatment − 2.51 (− 4.96 to − 0.06) 0.04
Follow‑up − 3.04 (− 5.32 to − 0.76) 0.01
Days of these difficulties present Pre‑treatment
Post‑treatment − 4.33 (− 7.90 to − 0.77) 0.02
Follow‑up − 2.84 (− 6.47 to 0.79) 0.12
Days of total disability Pre‑treatment
Post‑treatment − 2.51 (− 5.18 to 0.15) 0.06
Follow‑up − 1.69 (− 4.41 to 1.02) 0.22
Days of activity reduce Pre‑treatment
Post‑treatment − 3.15 (− 6.41 to 0.10) 0.06
Follow‑up − 1.95 (− 5.27 to 1.37) 0.25
Perceived social support Pre‑treatment
Post‑treatment 4.45 (− 1.05 to 9.95) 0.11
Follow‑up 2.52 (− 3.22 to 8.27) 0.39
PSYCHLOPS Pre‑treatment
Post‑treatment − 2.58 (− 4.39 to − 0.77) 0.006
Follow‑up − 1.66 (− 3.54 to 0.23) 0.08
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the ever-increasing demand for evidence-based, holis-
tic mental health services in low resource settings. Our 
study demonstrates that trans-diagnostic psychological 
intervention for CMDs can be delivered by non-special-
ists such as psychology graduates, in outpatient psychia-
try departments of low resource settings. Other studies 
in global mental health literature have reported similar 
findings where nurses, community health workers and 
peer volunteers have effectively delivered low intensity 
psychological interventions in low resource settings [6, 8, 
9, 36–39].
It may be expected that the study participants at the 
tertiary care facility in the current study would have more 
severe depression and anxiety symptoms than the partic-
ipants with the CMDs from community samples. Yet, the 
participants in both study arms had baseline scores on 
symptoms of anxiety and depression similar to the other 
studies [9, 10, 14] that have evaluated the effectiveness of 
PM + intervention in primary care and community set-
tings; the drop in the symptoms scores on HADS in the 
present study as a result of intervention is comparatively 
less. These observations may be explained by (a) reported 
high prevalence rates of psychological distress in human-
itarian settings [4, 5, 40]; (b) regression to mean phe-
nomena. Natural remission seems to be more frequent in 
mild and moderate cases of depression [1, 37, 41]; and (c) 
exclusion of patients with severe symptoms of CMDs and 
in need of in-patient care from the present study.
Limitations
This study demonstrates that the addition of PM + inter-
vention to routine care resulted in better treatment 
outcomes. However, there are a number of limitations 
which should be borne in mind when interpreting the 
study findings. First, we were able to follow only 67% of 
the sample at 20  weeks after baseline. This high drop-
out rate is expected in public mental health facilities 
and was accounted for in sample size calculations. Sec-
ond, while the literature reports long term gains of com-
bined treatment, we were able to follow-up patients for 
only 20  weeks. Third, we collected data on the use of 
psychotropic medicines using the CSRI, which may be 
subject to recall bias of study participants. Further stud-
ies may benefit from including larger sample size, longer 
term follow-up and objective data on the use of psycho-
tropic medications (such as an audit of hospital medical 
records). Lastly, the mean number of sessions attended by 
participants in the intervention arm was 2.86. Although, 
this is in keeping with compliance rates observed in 
the psychiatric outpatient department in public mental 
health facilities in low resource settings, this may raise 
concerns about the adequacy of the dose of interven-
tion received by the trial participants. A meta-regression 
analysis conducted by Cuijpers et  al. (2013) observed a 
small correlation between number of therapy sessions 
and treatment effects and this association was not signifi-
cant when the analysis adjusted for other characteristics 
of the studies [42]. This evidence suggests that even few 
but meaningful clinical interactions can benefit symptom 
improvement in patients with CMDs.
Conclusions
Results of the study demonstrate that the addition of 
PM + intervention to routine care resulted in better 
treatment outcome for the symptoms of anxiety and 
depression and improved functioning among outpatient 
attendees of a specialized mental health care facility in 
Pakistan. Specialized care facilities in LMICs may con-
sider adding brief, evidence-based psychological treat-
ments for CMDs to their routine care.
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